Tag Archives: Technology and Procedures

Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in one or more hematologic lines is necessary for the diagnosis of MDS. However, numerous reactive conditions other than MDS can cause cytopenia and these conditions must be distinguished from MDS. While dysplasia in hematologic cells is an indication of the diagnosis of MDS, the presence of mutations along with cytopenia is the most conclusive evidence for the diagnosis of MDS. Normal individuals above the age of 50 may show mutation in some genes (ASXL1, TET2, DNMT3, and TP53), however, the level (Variant allele frequency, VAF) […]

The FDA has Approved Drugs for FGFR Abnormalities

The FDA has Approved Drugs for FGFR Abnormalities

The FDA has approved Balversa (erdafitinib) as a treatment for adult patients with locally advanced or metastatic bladder cancer that have FGFR3 or FGFR2 abnormalities and that has progressed during or following prior platinum-containing chemotherapy. Urothelial tumors have been reported to show abnormalities in FGFR3 (22%), FGFR1 (8%), and FGFR2 (2%). These abnormalities involve mutations, fusion and amplification/overexpression. Abnormalities in FGFR can also be seen in various tumor types including lung (20%), breast (10%), melanoma (20%) rhabdomyosarcoma (7%), and cervical cancer (5%). Genomic Testing Cooperative (GTC) offers comprehensive testing of FGFR(1, 2, 3, and 4) covering mutations in all coding sequence, various fusions and expression levels. However, mutations studied in […]

GTC Presents at the 2019 ASCO Annual Meeting

GTC Presents at the 2019 ASCO Annual Meeting

Genomic Testing Cooperative (GTC) and Collaborators to Present data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019 ASCO Annual Meeting Irvine, California – May 22, 2019 – Genomic Testing Cooperative, LCA. today announced that data using its unique DNA and RNA profiling will be presented at the American Society of Clinical Oncology (ASCO) annual meeting.  In collaboration with University of California San Francisco, Fresno, CA and The University of Texas MD Anderson Cancer Center, Houston, TX, Genomic Testing Cooperative (GTC) used its proprietary DNA- and RNA-based profiling of diffuse large B-cell lymphoma (DLBCL) to study primary brain lymphoma.  While DLBCL is common, […]

Study shows that RNA Plus DNA profiling significantly enhanced Drug Matching

Study shows that RNA Plus DNA profiling significantly enhanced Drug Matching

Recent study published in Nature Medicine (Rodon et al, Nature Medicine volume 25, pages 751–758, 2019) showed that molecular profiling using both DNA and RNA significantly enhanced therapy recommendation and patient outcome.  A third of the studied patients got drug therapy recommendation when both RNA and DNA testing was performed. Genomic testing cooperative (GTC) offers combined RNA and DNA profiling without significant increase in cost.  Order GTC Solid Tumor PLUS or GTC Hematology PLUS for proper RNA and DNA profiling. In addition to DNA profiling (SNV, indels, TMB, and MSI), thorough molecular profiling requires RNA profiling.  GTC RNA testing provides important information on fusion/translocation (ALK, ROS1, RET, NTRK, BCR-ABL1, EWRS1, […]

INTERVIEW: Introduction to Genomic Testing Cooperative by Dr. Maher Albitar

INTERVIEW: Introduction to Genomic Testing Cooperative by Dr. Maher Albitar

A quick interview from Genomic Testing Cooperative founder, CEO/CMO, Dr. Albitar, introducing Genomic Testing Cooperative answering questions about it… Get all the  answers by watching the following video:  What is a precision diagnosis? What makes GTC different? What is the co-op model? How does GTC deliver value in genomic testing? How does GTC use artificial intelligence? How does GTC disrupt the genomic testing market? What will be reported from GTC testing? How do you support community-based labs? How does GTC model contribute to companion testing?

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers | ASH ANNUAL MEETING ABSTRACT

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers | ASH ANNUAL MEETING ABSTRACT

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations. Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib Program: Oral and Poster Abstracts | Monday, December 3, 2018: 11:45 AM Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: Advances in CLL Using Novel Combination Therapy Introduction: We previously reported a prognostic scoring system in CLL using pre-treatment factors in patients treated with ibrutinib [Ahn et al, 2016 ASH Annual Meeting]. Here we present long-term follow-up results and validation of the prognostic models in a large independent cohort of patients. We also determine the incidence […]

Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit | ASH ANNUAL MEETING ABSTRACT

Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit | ASH ANNUAL MEETING ABSTRACT

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Program: Oral and Poster Abstracts | Monday, December 3, 2018, 6:00 PM-8:00 PM Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Background: Venetoclax (VEN) is a potent and selective small molecule BCL2 inhibitor, with activity both as a single agent in relapsed/refractory AML, and in frontline combinations with hypomethylating agents and low-dose cytarabine. The ability of VEN to reduce the apoptotic threshold indicates it may be effective in combination with genotoxic agents which induce apoptosis, such as the FLAG-IDA regimen. Objectives: A Phase 1b/2 clinical trial was designed to assess the safety […]

Acute Myeloid Leukemia | ASH Annual Meeting Abstract

Acute Myeloid Leukemia | ASH Annual Meeting Abstract

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Saturday, December 1, 2018, 6:15 PM-8:15 PM | Hall GH (San Diego Convention Center) Background: Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are heterogeneous groups of disorders with a spectrum of clinical presentations and outcomes. Prognosis depends on various factors including age, karyotype, performance status, previous treatments, and mutation status. Genetic profiling with next generation sequencing (NGS) is increasingly being used at diagnosis to detect presence of somatic mutations for […]

Before you go...Let's stay in touch!
Subscribe on our list

- Get the Latest News
- Get Notified on upcoming events

* Your email is safe with us. We hate spamming, as much as you do!